Darolutamide

證據等級: L5

預測適應症: 3 個

Darolutamide: From Prostate Cancer to Homozygous Familial Hypercholesterolemia

One-Sentence Summary

Darolutamide is a non-steroidal androgen receptor (AR) antagonist approved for prostate cancer treatment in multiple jurisdictions. The TxGNN model predicts it may be effective for Homozygous Familial Hypercholesterolemia (HoFH), however no clinical trials or published literature currently support this direction, and mechanistic analysis reveals a fundamental logical break in the proposed pathway. All three top predictions carry a Hold recommendation.

Quick Overview

Item	Content
Original Indication	Not available from Taiwan regulatory data (not marketed in Taiwan); darolutamide is approved for prostate cancer in other jurisdictions
Predicted New Indication	Homozygous Familial Hypercholesterolemia (HoFH)
TxGNN Prediction Score	99.11%
Evidence Level	L5
Taiwan Market Status	✗ Not marketed
Number of Licenses	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from this evidence pack. Based on the mechanistic context provided in the repurposing rationale, darolutamide is an androgen receptor (AR) antagonist — its class mechanism involves blocking AR signaling, which is central to prostate cancer progression.

The theoretical bridge to HoFH relies on a two-step pathway: androgens (particularly DHT) are known to upregulate PCSK9 expression, which in turn suppresses hepatic LDL receptor (LDL-R) density. Blocking AR with darolutamide could theoretically relieve this PCSK9-mediated suppression, increasing LDL-R expression and improving LDL clearance.

However, this pathway contains a fundamental logical break for HoFH specifically. HoFH is caused by biallelic loss-of-function mutations in the LDLR gene (or variants in APOB, PCSK9, or LDLRAP1). Even if darolutamide successfully upregulated LDL-R transcription via PCSK9 derepression, functional receptors would remain absent due to the underlying genetic defect — lipoprotein clearance cannot be restored. The TxGNN high score (0.991) most likely reflects non-specific knowledge graph node neighborhood similarity (shared metabolic pathway nodes) rather than a genuine therapeutic signal.

Clinical Trial Evidence

Currently no related clinical trials registered for darolutamide in homozygous familial hypercholesterolemia.

Literature Evidence

Currently no related literature available for darolutamide in homozygous familial hypercholesterolemia.

Taiwan Market Information

Darolutamide has no Taiwan FDA authorizations at the time of this report. The drug is not marketed in Taiwan.

Item	Status
Market Status	Not marketed
Total Licenses	0
Available Dosage Forms	—

Cytotoxicity

Darolutamide is an androgen receptor antagonist used in oncology (prostate cancer). It is classified as a targeted anticancer therapy.

Item	Content
Cytotoxicity Classification	Targeted therapy — Non-steroidal androgen receptor antagonist (not conventional cytotoxic)
Myelosuppression Risk	Low (AR antagonists do not directly suppress bone marrow)
Emetogenicity Classification	Low
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Standard oral oncology drug handling; cytotoxic handling precautions not typically required for AR antagonists, but confirm per institutional policy

Safety Considerations

Please refer to the package insert for safety information. No Taiwan FDA label data, no drug interaction records, and no key warnings or contraindications data are available in this evidence pack.

Conclusion and Next Steps

Decision: Hold

Rationale: The top TxGNN prediction (HoFH) carries zero supporting clinical or literature evidence (L5), and the proposed mechanistic pathway has a clearly identified logical break — HoFH patients lack functional LDL receptors due to biallelic LDLR mutations, rendering the AR → PCSK9 → LDL-R derepression hypothesis therapeutically inert. The remaining two predictions (multiple endocrine neoplasia at L4, HIV infectious disease at L5) are similarly unsupported and, in the case of HIV, mechanistically counterindicated. The high TxGNN scores across all three indications likely reflect graph topology artifacts rather than pharmacological relevance.

To proceed, the following is needed:

Mechanism of action data (MOA): Retrieve full DrugBank entry (DB12941) to confirm receptor binding profile, pharmacokinetics, and any off-target activities
Taiwan/FDA label review: Download and parse the originator package insert (Nubeqa®) for approved indications, warnings, contraindications, and DDI profile
Preclinical data search: Conduct targeted literature search for any in vitro or in vivo studies examining darolutamide effects on LDL metabolism, PCSK9 expression, or lipid profiles before escalating to clinical feasibility assessment
Biomarker-stratified hypothesis: If AR expression has been documented in HoFH-adjacent lipid disorders (e.g., heterozygous FH or polygenic hypercholesterolemia without LDLR null mutation), a narrower biomarker-selected subpopulation hypothesis could be re-evaluated — but this would require new mechanistic studies, not just evidence retrieval
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.